ライフサイエンスコーパス: poorly-differentiated

1 epithelioid and sarcomatous components), or poorly differentiated.

2 , while 14 (15.1%) cases were categorized as poorly differentiated.

3 Thirty percent of tumors were poorly differentiated.

4 ned antigrowth activity of genistein against poorly differentiated 253J B-V human bladder cancer cell

5 beta-catenin localization were restricted to poorly differentiated [7 of 28 (25%) and 6 of 28 cases (

6 kidney tubular epithelia of KO animals were poorly differentiated, a phenotype reminiscent of human

7 (S175A)-expressing cells formed enlarged and poorly differentiated acini.

8 and natural killer (NK) cells compared with poorly differentiated adenocarcinoma observed in untreat

9 The surgical pathology showed a poorly differentiated adenocarcinoma with signet ring ce

10 well-differentiated adenocarcinoma, WD; and poorly differentiated adenocarcinoma, PD], the expressio

11 differentiated adenocarcinoma; and grade 5, poorly differentiated adenocarcinoma.

12 SIRT1 expression was increased in mice with poorly differentiated adenocarcinomas and in human prost

13 IRT1 was significantly elevated in mice with poorly differentiated adenocarcinomas compared with thos

14 Poorly differentiated, aggressive cancers often overexpr

15 r (PTC) was diagnosed in 97% of patients and poorly differentiated/anaplastic TC in 1.1%.

16 Jarid2, like Ezh2, is present in poorly differentiated and actively dividing cells, while

17 r cancers, CD73 is markedly downregulated in poorly differentiated and advanced-stage endometrial car

18 s-c-myc transgene, which on its own produced poorly differentiated and aggressive tumors.

19 ors that metastasized, five of six that were poorly differentiated and all that were assigned a Gleas

20 l-differentiated papillary thyroid cancer to poorly differentiated and anaplastic carcinomas, both in

21 n progression, as they were only detected in poorly differentiated and anaplastic carcinomas.

22 genes identified in a large series of human poorly differentiated and anaplastic thyroid cancers scr

23 RN-ALK was found with a higher prevalence in poorly differentiated and anaplastic thyroid cancers, an

24 High CYP24A1 protein levels were seen in poorly differentiated and highly advanced stages of pros

25 tein in the tumor cells in 10 of 45 cases of poorly differentiated and highly aggressive carcinoma wi

26 Most notably, forced claudin-7 expression in poorly differentiated and highly metastatic SW620 colon

27 These tumors were highly vascularized, poorly differentiated and invasive and loss of expressio

28 reas no expression of MICA/B was detected in poorly differentiated and invasive colorectal tumors tha

29 nt decrease of PTPRM transcripts was seen in poorly differentiated and moderately differentiated tumo

30 8)Ga-DOTATOC appears promising especially in poorly differentiated and oxyphilic subtypes of DTC.

31 ferentiated human SCCs, Smad2-/- tumors were poorly differentiated and underwent epithelial-mesenchym

32 ion was further elevated with progression to poorly differentiated and undifferentiated carcinoma.

33 prevalence in tall-cell variant PTCs and in poorly differentiated and undifferentiated carcinomas ar

34 metastatic tumors, with the remainder being poorly differentiated and undifferentiated primary cance

35 tissue of origin determination restricted to poorly differentiated and undifferentiated primary cance

36 found to be slightly lower than that of the poorly differentiated and undifferentiated primary tumor

37 Poorly-differentiated and well-differentiated cancer cel

38 expressing wild-type ADAM9 had predominantly poorly differentiated, and in some cases significantly l

39 rm significantly larger, hyperproliferative, poorly differentiated, and locally invasive tumors in nu

40 atients have been found to have larger, more poorly differentiated, and more hormonally insensitive t

41 Histologically, such cancers are poorly differentiated, and most fall into the basal subg

42 illary, 2 follicular, 8 Hurthle cell, and 13 poorly differentiated) approximately 5 d after the thera

43 ll-differentiated tumor areas than it was in poorly differentiated areas, although this trend was not

44 ed from a breast tumour (histological grade; poorly differentiated) as 'tester' and from matched norm

45 the nonproductive stage, which arises in the poorly differentiated basal epithelial compartment of a

46 emonstrate that flow cytometric detection of poorly differentiated basal tumor cells (BTCs), as defin

47 lear plasmid in proliferating populations of poorly differentiated (basal-like) human keratinocytes a

48 In contrast, the HPV16 LCR from poorly differentiated, basal cell-like cells contained m

49 However, SUVauto poorly differentiated between responding and nonrespondi

50 asion and induced an epithelial phenotype in poorly differentiated breast cancer cells.

51 breast epithelium and loss of alpha2beta1 in poorly differentiated breast cancer.

52 ated during lactation, and is upregulated in poorly differentiated breast cancer.

53 richment Analysis (GSEA), we discovered that poorly differentiated breast cancers are enriched for th

54 olecule E-cadherin are often associated with poorly differentiated breast cancers, recent studies sho

55 a genotype was significantly associated with poorly-differentiated breast tumors (p = 0.04) in combin

56 ivision cycle 25C (CDC25C) overexpression in poorly differentiated BTCs and determined that CDC25C ex

57 displayed enlarged shoot meristems, open and poorly differentiated buds, and a higher rate of cell di

58 fferentiated cancer (WDC) but not late-stage poorly differentiated cancer (PDC).

59 quently down-regulated in adenocarcinoma and poorly differentiated cancer specimens than in squamous

60 t solid tumors, HCCs are believed to contain poorly differentiated cancer stem cell-like cells (CSCs)

61 cified subset analysis, PADT use in men with poorly differentiated cancer was associated with improve

62 ant lesions, well-differentiated cancer, and poorly differentiated cancer.

63 Poorly-differentiated cancer cells were generally more r

64 levels of monoamine oxidase A expression and poorly differentiated cancers by immunohistochemistry.

65 and protein level was almost undetectable in poorly differentiated cancers compared with the moderate

66 Patients with poorly differentiated cancers fared less well than those

67 Patients with poorly differentiated cancers having more than 11 pelvic

68 26; P < .0001) compared with patients having poorly differentiated cancers with 11 or fewer nodes rem

69 For pN0M0 moderately and poorly differentiated cancers, and all node-positive (pN

70 highly expressed during embryogenesis and in poorly differentiated cancers, and high levels portend a

71 were younger, more often had larger or more poorly differentiated cancers, had more comorbid illness

72 sion, whereas this ratio was reversed in the poorly differentiated cancers.

73 -moderately differentiated PDACs but weak in poorly differentiated cancers.

74 and completely prevented its progression to poorly differentiated carcinoma (74% incidence in contro

75 grade prostatic intraepithelial neoplasia to poorly differentiated carcinoma at a greatly accelerated

76 Reduction of Snail expression in a poorly differentiated carcinoma cell line by RNA interfe

77 Decreased expression of beta1-subunit in poorly differentiated carcinoma cell lines correlated wi

78 Here, we report that poorly differentiated carcinoma cell lines derived from

79 of the dorsolateral prostate occupied by the poorly differentiated carcinoma were significantly lower

80 The poorly differentiated carcinoma with t(15;19)(q13, p13.1

81 imilar regardless of histology (small-cell v poorly differentiated carcinoma) or primary site.

82 fferentiated adenocarcinoma, 56 patients had poorly differentiated carcinoma, and 104 patients had pe

83 r progression of prostate tumorigenesis into poorly differentiated carcinoma.

84 ted carcinoma and in almost all cells of the poorly differentiated carcinoma.

85 ures, 83% areas of invasion, and 48% foci of poorly differentiated carcinoma.

86 ) with striking nuclear atypia and invasive, poorly differentiated carcinoma.

87 follicular carcinomas), in 16 (55.2%) of 29 poorly differentiated carcinomas (PDCs), and in 15 (51.7

88 arly papillomatogenesis and rapidly produced poorly differentiated carcinomas (pdSCCs) with high BrdU

89 mplifying compartment that progresses to the poorly differentiated carcinomas that arise rapidly afte

90 mors derived from the transformed HMECs were poorly differentiated carcinomas that infiltrated throug

91 Histologically, these tumors are poorly differentiated carcinomas with occasional cysts a

92 overexpressing Bmi-1 and H-Ras, which formed poorly differentiated carcinomas with spindle cell featu

93 ut its expression is dramatically reduced in poorly differentiated carcinomas, a finding that paralle

94 oiter and invasive PTC, which transitions to poorly differentiated carcinomas.

95 MCF10A-Kras-shHOXA5 cells formed aggressive, poorly differentiated carcinomas.

96 Overexpression of miR-215 in poorly differentiated cell lines causes a decrease in cl

97 expression by Western blot analysis than the poorly differentiated cell lines DU-145 and PC-3.

98 concentrated at the luminal edge, whereas in poorly differentiated cells polarity is inverted and exp

99 ors tend to form solid nodules consisting of poorly differentiated cells with abundant cytoplasm.

100 ptotic pathway prevents the removal of these poorly differentiated cells, resulting in the retention

101 ay contribute to the transformation of these poorly differentiated cells.

102 rapeutic strategies for patients affected by poorly differentiated CNS tumors.

103 The poorly differentiated cognate amino acid-binding site in

104 Loss of CDX2 expression is seen in some poorly differentiated colon carcinomas in humans.

105 loss of CDX2 expression is a feature of some poorly differentiated colon carcinomas in humans.

106 induced) colitis promoted the development of poorly differentiated colonic adenocarcinoma in mice lac

107 ost with increasing mesenchymal phenotype in poorly differentiated CRC cell lines as a consequence of

108 expression due to Cdx-1 loss is a feature of poorly differentiated CRCs.

109 ovide a therapeutic benefit, particularly in poorly differentiated cSCC.

110 cantly fewer aberrations than moderately and poorly differentiated cSCCs; yet, despite a lower rate o

111 Improved survival was also observed in poorly differentiated disease.

112 Two false-negative results were related to poorly differentiated duodenal and prostatic NETs (G3).

113 confined cancer of 0.5 cm(3) or less without poorly differentiated elements.

114 us system (CNS-PNETs) are highly aggressive, poorly differentiated embryonal tumors occurring predomi

115 These tumors were poorly differentiated endometrial adenocarcinomas with p

116 s recently been linked to the development of poorly differentiated endometrial tumors, a lethal form

117 rentially altered in well-differentiated and poorly-differentiated endometrial cancers.

118 V-infected tumor cells in Kaposi sarcoma are poorly differentiated endothelial cells, expressing mark

119 nd imaging investigations in these otherwise poorly differentiated epilepsies.

120 Expression of ACE2 in poorly differentiated epithelia facilitated SARS spike (

121 NMC) belongs to a class of highly lethal and poorly differentiated epithelial cancers arising mainly

122 We report a patient with poorly differentiated epithelial thymic carcinoma who ha

123 Tumors were poorly differentiated ER-alpha and progesterone receptor

124 on revealed a higher mean vessel density and poorly differentiated extracellular matrix (ECM) in MDA-

125 edullary disease is typically an aggressive, poorly differentiated form of MM that confers inferior o

126 0% had metastatic disease and two thirds had poorly differentiated gastric or GEJ adenocarcinoma, wer

127 ly produced aggressive, highly branched, and poorly differentiated glandular-like structures in Matri

128 a PSA doubling time of 10 months or less or poorly differentiated (Gleason grade 8 to 10) cancer.

129 The ES signature is also present in poorly differentiated glioblastomas and bladder carcinom

130 nizing hormone gene, Lhb We demonstrate that poorly differentiated gonadotropes express a TET1 isofor

131 ulation was greater (p<0.05) in pathological poorly differentiated grade G3/G4 than in well-different

132 mass diagnoses an invasive ductal carcinoma, poorly differentiated (grade 3), with lymphovascular inv

133 Pathology review indicated a poorly differentiated, grade 3 invasive ductal carcinoma

134 r-cell foci, as well as pseudo-glandular and poorly differentiated HCCs, exhibited a normal or reduce

135 on imbalance map analysis revealed that more poorly differentiated hepatocellular carcinoma contain m

136 tumors containing mixtures of both well and poorly differentiated, highly proliferative follicular e

137 mor diameter > 8 cm, age > or = 55 years and poorly differentiated histologic grade were also signifi

138 ed hazard ratios for stage IV moderately and poorly differentiated histological grade were 1.63 [95%

139 moking exposure, larger tumor size, and more poorly differentiated histological grade.

140 her sites and the exclusion of patients with poorly differentiated histologies from trials focused on

141 MSI colon cancers frequently display a poorly differentiated histology for which the molecular

142 577 CRCs linked loss of villin expression to poorly differentiated histology in MSI and MSS tumors.

143 y sampled nodes, T4 lesions, perforation, or poorly differentiated histology.

144 We found that TCF3 is highly expressed in poorly differentiated human breast cancers, preferential

145 oblasts and histologically closely resembled poorly differentiated human breast carcinomas.

146 When actively dividing poorly differentiated human hepatoma-derived (Huh7) cell

147 a marked reduction in IKKalpha expression in poorly differentiated human SCCs and identified Ikkalpha

148 Consistent with the loss of Smad2 in poorly differentiated human SCCs, Smad2-/- tumors were p

149 xpression is downregulated in many advanced, poorly differentiated, human cancers.

150 ion, DNA damage, and partial polyploidy in a poorly differentiated, immortalized hepatocyte cell line

151 l (n = 6) differentiated in 97% of cases and poorly differentiated in one.

152 sts fostered a microenvironment conducive to poorly differentiated invading tumor cells, whereas feta

153 ere highly invasive, leading us to term them poorly differentiated invasive carcinomas (PDICs).

154 h EZH2 overexpression promotes the growth of poorly differentiated invasive carcinomas remains to be

155 f ERG, it promotes the development of a more poorly differentiated, invasive adenocarcinoma.

156 c overexpression leads to the development of poorly differentiated, invasive prostate cancer that is

157 However, the resulting tumors are poorly differentiated, invasive, and metastatic to the l

158 C), but little or no expression was found in poorly differentiated, later-staged invasive tumors.

159 ary differentiation that is downregulated in poorly differentiated lung adenocarcinoma.

160 ioventricular heart valves, and hypoplastic, poorly differentiated lungs.

161 pathological findings were consistent with a poorly differentiated malignancy, suggestive of metastat

162 cells in syngeneic mice led to formation of poorly differentiated mammary carcinomas.

163 entiated epithelial cells are converted into poorly differentiated, migratory and invasive mesenchyma

164 ancies found in unexpected locations or with poorly differentiated morphologies can pose a significan

165 Il24 coincided with the loss of RET/PTC3 in poorly differentiated mouse tumors.

166 Stage IV moderately and poorly differentiated mucinous adenocarcinomas have dist

167 edition's decision to combine moderately and poorly differentiated mucinous adenocarcinomas into a si

168 roximal colon, lymphocytic infiltrate, and a poorly differentiated, mucinous or signet ring appearanc

169 Cancer stem-like cells represent poorly differentiated multipotent tumor-propagating cell

170 %; moderately differentiated, n = 33; 35.5%; poorly differentiated, n = 26; 27.9%) (P < 0.05).

171 c disorders, preinvasive, microinvasive, and poorly differentiated neoplasms received the most attent

172 However, in poorly differentiated NETs, (18)F-FDG PET/CT plays a sig

173 In 11 (39.2%) of 28 patients with poorly differentiated NETs, the management decision was

174 pho-Akt protein expression was identified in poorly differentiated neuroblastomas.

175 that commonly consist of undifferentiated or poorly differentiated neuroblasts with unfavorable clini

176 Treatment for advanced poorly differentiated neuroendocrine carcinoma should pa

177 anding of the tumorigenesis and treatment of poorly differentiated neuroendocrine tumors.

178 rformed, and pathology yields a diagnosis of poorly differentiated non-small cell lung cancer (NSCLC;

179 nd ipsilateral mediastinal nodes confirmed a poorly differentiated non-small-cell carcinoma.

180 ells, BLU stable transfectants, derived from poorly-differentiated NPC HONE1 cells, suppress VEGF165,

181 r of fungiform taste buds, the prevalence of poorly differentiated or missing taste cells, and the in

182 53(Deltaosx1) double knockout mice developed poorly differentiated osteosarcomas that resemble human

183 a-DOTATOC PET/CT was significantly higher in poorly differentiated/oxyphilic carcinomas (4/4 patients

184 ressed high levels of NGAL but moderately to poorly differentiated PaCa cells (PANC-1 and MIAPaCa-2)

185 pression and chemosensitivity responses in a poorly differentiated pancreatic cancer cell line, MIA P

186 racterized a previously undescribed class of poorly differentiated PanNETs in the RIP1-Tag2 mouse mod

187 In particular, high grade, poorly-differentiated PanNETs have the worst patient pro

188 Poorly differentiated PCECs are uncoupled, and Ca(2+) in

189 s exhibited a high mitotic index, resembling poorly differentiated (PD)-PanNETs in human patients.

190 Our data demonstrate that L1 is expressed in poorly differentiated PDAC cells in situ and that threon

191 Syk expression is lost in poorly differentiated PDAC cells in vitro and in situ, a

192 corresponding to patients with moderately or poorly differentiated PDAC tumors, respectively.

193 The Ewing family of tumors are poorly differentiated pediatric solid tumors arising in

194 l translocation in Ewing tumors, a family of poorly differentiated pediatric tumors arising predomina

195 Poorly differentiated periampullary tumors had significa

196 at Lcn2-expressing breast tumors displayed a poorly differentiated phenotype and showed increased loc

197 stasis, and inhibition of progression to the poorly differentiated phenotype in primary prostatic tum

198 escaped fgfr1 deletion primarily exhibited a poorly differentiated phenotype.

199 Loss of CCN6 is associated with poorly differentiated phenotypes and increased invasion.

200 o retinas from crx-/crx- knockout mice (with poorly differentiated photoreceptors) demonstrated a 6-f

201 the 13 tumors with deletions, 12 were either poorly differentiated primary tumors or metastases of pr

202 bigenic mice we did not detect IGF-1(des) in poorly differentiated primary tumors or metastatic lesio

203 Metastatic cells formed rapidly growing, poorly differentiated primary tumors that metastasized.

204 loss of AR in both mouse models resulted in poorly differentiated primary tumors with expanded inter

205 rongly expressed in the endothelial cells of poorly differentiated prostate adenocarcinoma but not in

206 vasculature between well-differentiated and poorly differentiated prostate adenocarcinoma suggest th

207 rrow significantly reduced the hemorrhage in poorly differentiated prostate adenocarcinomas with bone

208 ars after diagnosis, men with moderately and poorly differentiated prostate cancer were more likely t

209 fferentiated), or high-GS cohorts (GS >/= 8, poorly differentiated prostate cancer).

210 7 of 13 (54%) control-treated mice developed poorly differentiated prostate cancer.

211 weeks) significantly inhibits progression to poorly differentiated prostate carcinoma and pulmonary m

212 ase in the number of well-differentiated and poorly differentiated prostates, coinciding with a 70% i

213 tion associated with a high Gleason's score, poorly differentiated prostatic adenocarcinoma.

214 xpression was also reduced in moderately and poorly differentiated prostatic tumors compared with wel

215 parts to be KRAS2 wild type, TP53 wild type, poorly differentiated, proximally located, occur at lowe

216 itivity to the VEGFR2 inhibitor sorafenib in poorly differentiated PTC cells.

217 eplicates in vivo than previous models using poorly differentiated rapidly dividing hepatoma cells.

218 In a poorly differentiated rat hepatoma, Morris hepatoma 3924

219 [moderately differentiated], and high-grade [poorly differentiated], respectively), chromogranin A, a

220 R-206, which are routinely lost in advanced, poorly differentiated rhabdomyosarcoma (RMS) but charact

221 Adult neu(+)/pfp(+) males developed poorly differentiated salivary carcinomas, whereas neu(+

222 of EWS-FLI1 shifted the tumor phenotype to a poorly differentiated sarcoma.

223 development and accelerates the formation of poorly differentiated sarcomas.

224 sent with tumors, mostly undifferentiated or poorly differentiated sarcomas.

225 and results in replacement of neck BAT with poorly differentiated skeletal muscle.

226 s identified as a heterozygous mutation in a poorly differentiated squamous cell carcinoma (SCC) and

227 a) expression in a large proportion of human poorly differentiated squamous cell carcinomas (SCC) and

228 e diffused but broadly expressed in well and poorly differentiated squamous cell carcinomas (SCC), in

229 on of moderately differentiated carcinoma to poorly differentiated state and distant metastasis.

230 g-deficient tumors showed a propensity for a poorly differentiated state with features of epithelial-

231 al lesions with a propensity to advance to a poorly differentiated state.

232 om a differentiated adenocarcinoma to a more poorly differentiated state.

233 is required for tumors to reach a primitive, poorly differentiated state.

234 medicine or as novel therapeutic targets for poorly differentiated, stem-like cancers.

235 HMGA1) gene is highly expressed in hESCs and poorly differentiated, stem-like cancers; however, its r

236 tva transgenic mice, we detected high-grade, poorly differentiated, stroma-rich and ER-negative tumor

237 imilar morphological phenotypes (high grade, poorly differentiated, stroma-rich and ER-negative), irr

238 ocytes, generate neurons poorly, form small, poorly differentiated teratomas, and cannot generate chi

239 Poorly differentiated thyroid cancer (PDTC) and anaplast

240 yroid cancers (PTC) that rapidly progress to poorly differentiated thyroid cancer (PDTC).

241 atic differentiated thyroid cancer (DTC) and poorly differentiated thyroid cancer (PDTC).

242 Patients with poorly differentiated thyroid cancers (PDTC), anaplastic

243 e histological features of human RAS-driven, poorly differentiated thyroid cancers.

244 cally invasive and have well-defined foci of poorly differentiated thyroid carcinoma (PDTC).

245 e thyroid tumors (for example, anaplastic or poorly differentiated thyroid carcinoma) carry several c

246 his pathway may promote redifferentiation in poorly differentiated thyroid carcinomas with constituti

247 0E), the mice developed highly penetrant and poorly differentiated thyroid tumors.

248 and impaired ESC differentiation, as seen in poorly differentiated TKO embryoid bodies (EBs) and tera

249 els of p120 caused a striking reversion from poorly differentiated to cobblestone-like epithelial mor

250 d no viable retinal tumor; the remainder had poorly differentiated tumor (6 eyes [50%]) or moderately

251 or size > 3 cm (HR 1.34 [range, 1.03-3.12]), poorly differentiated tumor (HR 3.18 [range, 1.31-7.70])

252 erts a strong promyogenic influence on these poorly differentiated tumor cells.

253 g and advanced, aggressive HCC subtypes with poorly differentiated tumor phenotypes.

254 In FaDu xenografts, a poorly differentiated tumor-expressing mutant p53, the c

255 ssion in colorectal carcinoma cell lines and poorly differentiated tumor-tissue specimens.

256 r (2% vs 9%) invasions (P < .001), and fewer poorly differentiated tumors (15% vs 28%; P < .001).

257 intake was stronger for serous invasive and poorly differentiated tumors (comparable HR: 0.68; 95% C

258 ake of somatostatin analog usually indicates poorly differentiated tumors (G3).

259 expression, CRKI and CRKII were increased in poorly differentiated tumors (P<0.05).

260 s stage I), larger (T(2-4) versus T(1)), and poorly differentiated tumors and in tumors from patients

261 When compared with wild-type mice, poorly differentiated tumors arising in FGF(+/-) and FGF

262 1 loss strongly accentuated the formation of poorly differentiated tumors characterized by increased

263 atients undergoing APR were older, with more poorly differentiated tumors evidencing less response to

264 Poorly differentiated tumors exhibited greater microvess

265 Poorly differentiated tumors have fewer mutations than w

266 Poorly differentiated tumors in non-small cell lung canc

267 ller and well-differentiated compared to the poorly differentiated tumors in wild-type mice.

268 present with advanced-stage disease and have poorly differentiated tumors or tumors with an unfavorab

269 In Id-deficient TRAMP mice, the poorly differentiated tumors show extensive hemorrhage,

270 We find that histologically poorly differentiated tumors show preferential overexpre

271 Poorly differentiated tumors showed a trend toward decre

272 d c-Myc are more frequently overexpressed in poorly differentiated tumors than in well-differentiated

273 l carcinomas (ECs) are estrogen independent, poorly differentiated tumors that behave in an aggressiv

274 cer, but curative treatments are elusive for poorly differentiated tumors where survival is just 15%

275 ia that progresses to highly pleomorphic and poorly differentiated tumors with basal characteristics.

276 tic impact and was enriched in patients with poorly differentiated tumors with high AFP levels as wel

277 of mice heterozygous for Ini1 presented with poorly differentiated tumors with variable rhabdoid feat

278 Twenty-eight patients (26.9%) had poorly differentiated tumors, and 76 (73.1%) had well-di

279 stage, pN+ stage tumors, larger tumor size, poorly differentiated tumors, and R1/2 resections were m

280 h pT3/4 stage, N+ tumors, larger tumor size, poorly differentiated tumors, and R1/2 resections.

281 al reactivity of each protein was reduced in poorly differentiated tumors, and there was a positive a

282 malignant progression, which is enriched in poorly differentiated tumors, and was highly predictive

283 "signature" phenotypes of highly malignant, poorly differentiated tumors, including hepatomas, is th

284 ming adenocarcinomas, and for characterizing poorly differentiated tumors, including neuroendocrine c

285 with a more advanced stage, and to have more poorly differentiated tumors.

286 s, male sex, distant/metastatic disease, and poorly differentiated tumors.

287 Similar diminishing effects were found for poorly differentiated tumors.

288 d 25.6% (95% CI, 23.7%-28.3%) for those with poorly differentiated tumors.

289 tion regulators that are highly expressed in poorly differentiated tumors.

290 popharyngeal primary sites and patients with poorly differentiated tumors.

291 , and its low expression can be a marker for poorly differentiated tumors.

292 ted tumors express lower levels of pp32 than poorly differentiated tumors.

293 well-differentiated tumors, it was absent in poorly differentiated tumors.

294 rmore, we were able to successfully classify poorly differentiated tumours using miRNA expression pro

295 -1 negativity is pathognomonic of high-grade poorly differentiated tumours.

296 relation studies documented progression from poorly differentiated viable HCC tissues before treatmen

297 could be attributable to low visual acuity, poorly differentiated visual brain areas, or small absol

298 tly higher proportion of HCC cases graded as poorly differentiated (well-differentiated, n = 34; 36.6

299 nd pertuzumab expressed EMT markers and were poorly differentiated, whereas tumors exposed to the com

300 is that led to the diagnosis of an ulcerated poorly differentiated (with signet ring cells) adenocarc